V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 180006303 | 180004018 | null | null | null | null | 2018-04-12 | NIVOLUMAB | null | null | PEMBROLIZUMAB | 100648840 |
| 180006682 | 180004025 | 1.38 | null | null | null | 2021-02-08 | LENVATINIB | null | null | LIPOSOMAL DOXORUBICIN | 100826724 |
| 180006703 | 180004026 | null | null | null | 2017-10-24 | 2017-12-19 | Dinutuximab Beta | null | null | CABOZANTINIB | 101684845 |
| 180006729 | 180004027 | null | null | null | 2017-06-10 | 2018-01-26 | MITOTANE | null | null | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 101645286 |
| 180007162 | 180004034 | null | null | null | null | 2019-07-01 | Cisplatin+Doxorubicin+Etoposide 28d | null | null | CABOZANTINIB | 101322782 |
| 180007308 | 180004037 | null | null | null | null | 2018-08-15 | NB HRNBL-1 COJEC Ind COURSE B | null | null | NB HRNBL-1 ISOTRETINOIN | 101258134 |
| 180008066 | 180004041 | null | null | null | 2016-12-02 | 2016-12-02 | Cisplatin+Doxorubicin+Etoposide 28d | null | null | NB HRNBL-1 ISOTRETINOIN | 100938621 |
| 180008440 | 180004045 | null | null | null | null | 2020-06-08 | null | null | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101358012 |
| 180008824 | 180004050 | null | null | null | null | 2016-11-27 | PEMBROLIZUMAB | null | null | EVEROLIMUS + EXEMESTANE | 100891060 |
| 180009270 | 180004053 | null | null | null | null | 2020-11-28 | CNS ATRT ICE Ifos/Carboplatin/Etoposide + GCSF | null | null | LENVATINIB | 100217581 |
| 180009623 | 180004057 | null | null | null | 2019-02-07 | 2019-07-25 | Oxaliplatin + Modified de Gramont | null | null | CABOZANTINIB | 100674591 |
| 180009685 | 180004058 | null | null | null | 2018-11-01 | 2018-11-22 | BUSULFAN + MELPHALAN | null | null | NB RELAPSED CYCLOPHOSPHAMIDE AND TOPOTECAN | 101809073 |
| 180010022 | 180004061 | null | null | null | null | 2019-03-18 | LENVATINIB | null | null | DINUTUXIMAB BETA | 101373516 |
| 180010221 | 180004062 | null | null | null | null | 2016-09-13 | R GCVP | null | null | NB HRNBL-1 ISOTRETINOIN | 100590552 |
| 180010484 | 180004066 | 0 | null | null | 2022-03-31 | 2022-04-03 | CNS GCT II Non Germin - Std PEI | null | null | LENVATINIB | 101493526 |
| 180010572 | 180004067 | null | null | null | null | 2020-11-27 | Trial Unspecified | null | null | TRIAL UNSPECIFIED | 101806533 |
| 180010584 | 180004068 | null | null | null | null | 2021-08-23 | NB HRNBL-1 Isotretinoin | null | null | NOT MATCHED | 101352034 |
| 180010694 | 180004070 | null | null | null | 2022-04-21 | 2022-04-22 | Mitotane 2g | null | null | CABOZANTINIB | 100172820 |
| 180011222 | 180004074 | null | null | null | null | 2021-07-22 | Irinotecan + Temozolomide | null | null | NOT MATCHED | 100348590 |
| 180011561 | 180004078 | null | null | null | 2022-04-19 | 2022-05-02 | Trial Unspecified | null | null | LENVATINIB | 101161065 |
| 180012596 | 180004089 | null | null | null | null | 2018-06-09 | LENVATINIB | null | null | MITOTANE | 101425806 |
| 180012614 | 180004090 | null | null | null | null | 2020-08-01 | NB Rel CCLG guidelines Cyclo/topo | null | null | NB HRNBL-1 ISOTRETINOIN | 101753834 |
| 180012941 | 180004092 | null | null | null | 2019-07-08 | 2019-07-20 | LENVATINIB | 99 | null | CABOZANTINIB | 100218966 |
| 180012978 | 180004093 | null | null | null | null | 2021-05-31 | NB Low/Intermed risk guidelines CADO | null | null | TEMOZOLOMIDE | 101626024 |
| 180013161 | 180004095 | null | null | null | null | 2019-07-23 | null | null | null | CARBOPLATIN + LIPOSOMAL DOX | 100544387 |
| 180006891 | 180004103 | null | null | null | null | 2020-09-24 | LANREOTIDE | null | null | ANTIBODY NBL | 100509469 |
| 180009463 | 180004105 | null | null | null | 2022-01-29 | 2022-02-10 | NB relapse Temozolamide/ topotecan | null | null | CARBOPLATIN + RT | 100961749 |
| 180000098 | 180004110 | 0 | null | null | null | 2019-04-10 | NB HRNBL-1 Isotretinoin | null | null | CABOZANTINIB | 101425257 |
| 180001855 | 180004119 | null | null | null | 2021-01-22 | 2021-05-01 | LENVATINIB | null | null | DINUTUXIMAB BETA | 100849373 |
| 180003150 | 180004121 | 1.58 | null | null | 2017-03-13 | 2017-11-29 | CABOZANTINIB | null | null | CISPLATIN + DOXORUBICIN | 100759506 |
| 180003594 | 180004125 | null | null | null | null | 2017-10-04 | NB HRNBL-1 ch14.18/CHO only (trial) | null | null | LENVATINIB | 101446736 |
| 180003609 | 180004126 | null | null | null | 2021-08-23 | 2021-09-13 | Olaparib | null | null | VINORELBINE | 100996924 |
| 180003628 | 180004128 | null | null | null | null | 2018-06-29 | null | null | null | DOCETAXEL | 101269336 |
| 180003921 | 180004131 | null | null | null | 2021-04-15 | 2021-04-27 | Irinotecan + Modified De Gramont | null | null | NB BEACON DINUTUXIMAB + TEMOZOLOMIDE | 100667986 |
| 180004626 | 180004138 | null | null | null | null | 2016-07-13 | Carboplatin + Pemetrexed | null | null | FLUOROURACIL + OXALIPLATIN | 101486943 |
| 180005369 | 180004142 | null | null | null | null | 2016-12-28 | Antibody NBL | null | null | CARBOPLATIN | 101475349 |
| 180005449 | 180004143 | null | null | null | 2021-10-28 | 2021-11-06 | null | null | null | OXALIPLATIN + MDG | 100345088 |
| 180006180 | 180004148 | 0 | null | null | 2017-01-28 | 2018-02-13 | CISPLATIN + DOX + ETOPOSIDE + MITOTANE | null | null | LENVATINIB | 101423045 |
| 180006482 | 180004151 | null | null | null | 2022-03-01 | 2022-03-02 | CABOZANTINIB | null | null | CABOZANTINIB | 101450779 |
| 180006580 | 180004154 | null | null | null | 2018-09-16 | 2018-09-20 | CNS ATRT VCA Vinc/Dactino/Cyclophos + GCSF | null | null | PACLITAXEL | 100809680 |
| 180008066 | 180004164 | null | null | null | 2016-11-11 | 2016-12-02 | Dinutuximab Beta | null | null | CYCLOPHOSPHAMIDE + VINCRISTINE | 100938621 |
| 180008239 | 180004165 | null | null | null | null | 2016-09-05 | Dinutuximab Beta | null | null | ABEMACICLIB + FULVESTRANT | 100964595 |
| 180008364 | 180004166 | null | null | null | 2021-07-18 | 2022-01-06 | Docetaxel 100mg/m2 (21 day) | null | null | TEMOZOLOMIDE | 100879292 |
| 180009316 | 180004171 | null | null | null | 2022-05-22 | 2022-05-22 | CARBOPLATIN + ETOPOSIDE | null | null | PEMBROLIZUMAB | 101571675 |
| 180011448 | 180004187 | null | null | null | null | 2018-03-29 | NB HRNBL-1 COJEC Ind COURSE A | null | null | TRIAL | 100299274 |
| 180012205 | 180004193 | null | null | null | 2021-03-22 | 2021-04-18 | NB HRNBL-1 Isotretinoin | null | null | CABOZANTINIB | 100400920 |
| 180012367 | 180004194 | null | null | null | 2012-07-03 | 2012-07-17 | CNS GCT II Germinoma - Ifos Etop | null | null | PEMBROLIZUMAB | 100785100 |
| 180012640 | 180004198 | null | null | null | null | 2021-10-24 | Dinutuximab Beta | null | null | TEMOZOLOMIDE | 101299721 |
| 180012978 | 180004200 | null | null | null | null | 2021-06-01 | NB HRNBL-1 COJEC Ind COURSE C | null | null | EVEROLIMUS + EXEMESTANE | 101626024 |
| 180012294 | 180004209 | null | null | null | 2020-02-15 | 2020-02-23 | NB HRNBL-1 TVD | null | null | VANDETANIB | 100332877 |